Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Voorraadrapport

Marktkapitalisatie: US$358.8m

Amylyx Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Amylyx Pharmaceuticals is Josh Cohen, benoemd in Jan2013, heeft een ambtstermijn van 11.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.42M, bestaande uit 8.4% salaris en 91.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.26% van de aandelen van het bedrijf, ter waarde $ 15.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 3.8 jaar.

Belangrijke informatie

Josh Cohen

Algemeen directeur

US$7.4m

Totale compensatie

Percentage CEO-salaris8.4%
Dienstverband CEO11.8yrs
Eigendom CEO4.3%
Management gemiddelde ambtstermijn3.9yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 25

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10
Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16
This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16
Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Analyse CEO-vergoeding

Hoe is Josh Cohen's beloning veranderd ten opzichte van Amylyx Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$259m

Jun 30 2024n/an/a

-US$166m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$7mUS$621k

US$49m

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$149m

Dec 31 2022US$7mUS$539k

-US$198m

Sep 30 2022n/an/a

-US$184m

Jun 30 2022n/an/a

-US$153m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$1mUS$418k

-US$88m

Sep 30 2021n/an/a

-US$68m

Dec 31 2020US$671kUS$370k

-US$42m

Compensatie versus markt: De totale vergoeding ($USD 7.42M ) Josh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).

Compensatie versus inkomsten: De vergoeding van Josh is gestegen terwijl het bedrijf verliesgevend is.

CEO

Josh Cohen (32 yo)

11.8yrs

Tenure

US$7,418,169

Compensatie

Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Joshua Cohen
Co-Founder11.8yrsUS$7.42m4.26%
$ 15.3m
Justin Klee
Co-Founder11.8yrsUS$7.42m4.2%
$ 15.1m
James Frates
Chief Financial Officer3.8yrsUS$3.51m0.14%
$ 509.8k
Gina Mazzariello
Chief Legal Officer & General Counsel2.8yrsUS$3.01m0.21%
$ 752.4k
Camille Bedrosian
Chief Medical Officerless than a yearUS$2.37m0.030%
$ 108.2k
Tom Holmes
Chief Technical Operations Officerno datageen gegevensgeen gegevens
Lindsey Allen
Head of Investor Relations & Communicationsno datageen gegevensgeen gegevens
Shauna Horvath
Head of Global Marketing3.9yrsgeen gegevensgeen gegevens
Linda Arsenault
Chief Human Resources Officerless than a yeargeen gegevensgeen gegevens
Chris Aiello
Head of Canada & GM3.6yrsgeen gegevensgeen gegevens
Keith White
Head of Global Market Access3.9yrsgeen gegevensgeen gegevens
Tammy Sarnelli
Global Head of Regulatory Affairs4.3yrsgeen gegevensgeen gegevens

3.9yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AMLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Joshua Cohen
Co-Founder10.8yrsUS$7.42m4.26%
$ 15.3m
Justin Klee
Co-Founder10.8yrsUS$7.42m4.2%
$ 15.1m
Peter Finn
Company Secretary & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Walter Gilbert
Special Advisor & Member of Advisory Board3.8yrsUS$51.24kgeen gegevens
George Milne
Independent Chairman of the Board9.8yrsUS$385.07k1.26%
$ 4.5m
Rudolph Tanzi
Chairman of The Scientific Advisory Boardno datageen gegevensgeen gegevens
Alan Walts
Board Observer & Advisor7.3yrsgeen gegevensgeen gegevens
Karen Firestone
Independent Director1.7yrsUS$681.15k0.081%
$ 289.8k
Daphne Quimi
Independent Director3.4yrsUS$348.59k0.0073%
$ 26.3k
Bernhardt G. Zeiher
Independent Directorless than a yeargeen gegevensgeen gegevens
Sasha Bakhru
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paul Fonteyne
Independent Director3.7yrsUS$342.12k0.0058%
$ 20.8k

3.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AMLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).